Functional analysis of the SEPT9-ABL1 chimeric fusion gene derived from T-prolymphocytic leukemia

Leukemia Research

Volumn 38, Issue 12, 2014, Pages 1451-1459

  Kawai, Hidetsugu ^a   Matsushita, Hiromichi ^a,b   Suzuki, Rikio ^a   Sheng, Yin ^a   Lu, Jun ^a   Matsuzawa, Hideyuki ^a   Yahata, Takashi ^a   Tsuma Kaneko, Mitsuyo ^a   Tsukamoto, Hideo ^a   Kawada, Hiroshi ^a   Ogawa, Yoshiaki ^a   Ando, Kiyoshi ^a,b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

ABL1 fusion gene; SEPT9 ABL1; Tyrosine kinase inhibitors

Indexed keywords

ABELSON KINASE; ABELSON KINASE 1; BCR ABL PROTEIN; CRK LIKE PROTEIN; DASATINIB; IMATINIB; INTERLEUKIN 3; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SEPTIN; SEPTIN 9; SEPTIN 9A; SEPTIN 9B; SEPTIN 9D; SEPTIN 9E; SEPTIN 9F; STAT5 PROTEIN; UNCLASSIFIED DRUG; ISOPROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; SEPT9 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER RESISTANCE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG DOSE COMPARISON; DRUG SENSITIVITY; FUSION GENE; GENE FUNCTION; GENETIC ANALYSIS; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROLYMPHOCYTIC LEUKEMIA; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SEPT9 ABL1 CHIMERIC FUSION GENE; SOLID TUMOR; SURVIVAL RATE; TREATMENT DURATION; TUMOR INVASION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; LEUKEMIA, PROLYMPHOCYTIC, T-CELL; METABOLISM; PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; LEUKEMIA, PROLYMPHOCYTIC, T-CELL; MICE; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; SEPTINS; STAT5 TRANSCRIPTION FACTOR;

EID: 84916218774     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.08.015     Document Type: Article

References (41)

1. Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal 2010, 3:re6.
2. Greuber E.K., Smith-Pearson P., Wang J., Pendergast A.M. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 2013, 13:559-571.
3. Quintas-Cardama A., Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009, 113:1619-1630.
4. De Braekeleer E., Douet-Guilbert N., Rowe D., Bown N., Morel F., Berthou C., et al. ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol 2011, 86:361-371.
5. Suzuki R., Matsushita H., Kawai H., Matsuzawa H., Tsuboi K., Watanabe S., et al. Identification of a novel SEPT9-ABL1 fusion gene in a patient with T-cell prolymphocytic leukemia. Leuk Res Rep 2014, 3:54-57.
6. Hall P.A., Russell S.E. The pathobiology of the septin gene family. J Pathol 2004, 204:489-505.
7. Leipe D.D., Wolf Y.I., Koonin E.V., Aravind L. Classification and evolution of P-loop GTPases and related ATPases. J Mol Biol 2002, 317:41-72.
8. Cerveira N., Bizarro S., Teixeira M.R. MLL-SEPTIN gene fusions in hematological malignancies. Biol Chem 2011, 392:713-724.
9. Connolly D., Abdesselam I., Verdier-Pinard P., Montagna C. Septin roles in tumorigenesis. Biol Chem 2011, 392:725-738.
10. Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B., Quackenbush R.C., et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998, 92:3780-3792.
11. Harada Y., Inoue D., Ding Y., Imagawa J., Doki N., Matsui H., et al. RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes. Blood 2013, 121:3434-3446.
12. Warsch W., Grundschober E., Berger A., Gille L., Cerny-Reiterer S., Tigan A.S., et al. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget 2012, 3:1669-1687.
13. Feller S.M., Posern G., Voss J., Kardinal C., Sakkab D., Zheng J., et al. Physiological signals and oncogenesis mediated through Crk family adapter proteins. J Cell Physiol 1998, 177:535-552.
14. Vigneri P., Wang J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001, 7:228-234.
15. McWhirter J.R., Wang J.Y. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 1991, 11:1553-1565.
16. Warsch W., Grundschober E., Sexl V. Adding a new facet to STAT5 in CML: multitasking for leukemic cells. Cell Cycle 2013, 12:1813-1814.
17. Peterson E.A., Kalikin L.M., Steels J.D., Estey M.P., Trimble W.S., Petty E.M. Characterization of a SEPT9 interacting protein, SEPT14, a novel testis-specific septin. Mamm Genome 2007, 18:796-807.
18. Landsverk M.L., Ruzzo E.K., Mefford H.C., Buysse K., Buchan J.G., Eichler E.E., et al. Duplication within the SEPT9 gene associated with a founder effect in North American families with hereditary neuralgic amyotrophy. Hum Mol Genet 2009, 18:1200-1208.
19. De Keersmaecker K., Graux C., Odero M.D., Mentens N., Somers R., Maertens J., et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 2005, 105:4849-4852.
20. Graux C., Cools J., Melotte C., Quentmeier H., Ferrando A., Levine R., et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36:1084-1089.
21. Gancheva K., Virchis A., Howard-Reeves J., Cross N.C., Brazma D., Grace C., et al. Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review. Mol Cytogenet 2013, 6:39.
22. Quintas-Cardama A., Tong W., Manshouri T., Vega F., Lennon P.A., Cools J., et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia 2008, 22:1117-1124.
23. Mustjoki S., Hernesniemi S., Rauhala A., Kahkonen M., Almqvist A., Lundan T., et al. A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica 2009, 94:1469-1471.
24. Deenik W., Beverloo H.B., van der Poel-van de Luytgaarde S.C., Wattel M.M., van Esser J.W., Valk P.J., et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia 2009, 23:627-629.
25. Tomita O., Iijima K., Ishibashi T., Osumi T., Kobayashi K., Okita H., et al. Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1. Leuk Res 2014, 38:361-370.
26. 50. Oncologist 2011, 16:868-876.
27. Luo F.R., Yang Z., Camuso A., Smykla R., McGlinchey K., Fager K., et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006, 12:7180-7186.
28. Cilloni D., Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res 2012, 18:930-937.
29. Barila D., Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 1998, 18:280-282.
30. Russell S.E., McIlhatton M.A., Burrows J.F., Donaghy P.G., Chanduloy S., Petty E.M., et al. Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. Cancer Res 2000, 60:4729-4734.
31. Montagna C., Lyu M.S., Hunter K., Lukes L., Lowther W., Reppert T., et al. The Septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines. Cancer Res 2003, 63:2179-2187.
32. Scott M., Hyland P.L., McGregor G., Hillan K.J., Russell S.E., Hall P.A. Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours. Oncogene 2005, 24:4688-4700.
33. Wasserkort R., Kalmar A., Valcz G., Spisak S., Krispin M., Toth K., et al. Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. BMC Cancer 2013, 13:398.
34. Dietrich D., Jung M., Puetzer S., Leisse A., Holmes E.E., Meller S., et al. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions. PLOS ONE 2013, 8:e84225.
35. Burrows J.F., Chanduloy S., McIlhatton M.A., Nagar H., Yeates K., Donaghy P., et al. Altered expression of the septin gene, SEPT9, in ovarian neoplasia. J Pathol 2003, 201:581-588.
36. Scott M., McCluggage W.G., Hillan K.J., Hall P.A., Russell S.E. Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. Int J Cancer 2006, 118:1325-1329.
37. Connolly D., Hoang H.G., Adler E., Tazearslan C., Simmons N., Bernard V.V., et al. Septin 9 amplification and isoform-specific expression in peritumoral and tumor breast tissue. Biol Chem 2014, 395:157-167.
38. Amir S., Mabjeesh N.J. SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubule-disrupting agents. Cancer Biol Ther 2007, 6:1926-1931.
39. Gonzalez M.E., Makarova O., Peterson E.A., Privette L.M., Petty E.M. Up-regulation of SEPT9_v1 stabilizes c-Jun-N-terminal kinase and contributes to its pro-proliferative activity in mammary epithelial cells. Cell Signal 2009, 21:477-487.
40. Golan M., Mabjeesh N.J. SEPT9_i1 is required for the association between HIF-1α and importin-α to promote efficient nuclear translocation. Cell Cycle 2013, 12:2297-2308.
41. Chacko A.D., McDade S.S., Chanduloy S., Church S.W., Kennedy R., Price J., et al. Expression of the SEPT9_i4 isoform confers resistance to microtubule-interacting drugs. Cell Oncol 2012, 35:85-93.